What is HC Wainwright’s Estimate for MOLN Q1 Earnings?

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Molecular Partners in a note issued to investors on Tuesday, January 27th. HC Wainwright analyst R. Burns expects that the company will earn ($0.41) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.93) per share. HC Wainwright also issued estimates for Molecular Partners’ Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($0.45) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.39) EPS and FY2027 earnings at ($1.64) EPS.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.05.

Several other equities analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a report on Monday, December 22nd. JPMorgan Chase & Co. reduced their price objective on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a research note on Monday, December 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $9.58.

Molecular Partners Stock Performance

NASDAQ:MOLN opened at $4.15 on Wednesday. Molecular Partners has a 52 week low of $3.36 and a 52 week high of $5.35. The firm has a 50-day moving average price of $4.23 and a two-hundred day moving average price of $3.94. The firm has a market cap of $167.42 million, a price-to-earnings ratio of -2.16 and a beta of 1.07.

Molecular Partners News Summary

Here are the key news stories impacting Molecular Partners this week:

• Positive Sentiment: HC Wainwright began coverage and assigned a Buy / Strong‑Buy rating with a $13.00 price target (about a 213% upside vs. the recent price), a clear catalyst drawing investor interest and buying pressure. Read More.
• Positive Sentiment: The analyst (R. Burns) published forward estimates that show improving losses: HC Wainwright models FY2026 EPS of -$1.70 and FY2027 EPS of -$1.64, which are less negative than the current consensus (~ -$1.93). That relative improvement underpins the bullish price target and supports upside expectations. Read More.
• Neutral Sentiment: HC Wainwright also released quarter‑by‑quarter EPS projections (Q1–Q4 2026 and Q1–Q4 2027: ~ -$0.39 to -$0.45), giving investors a detailed roadmap but no near‑term profitability signal; these are model assumptions rather than confirmed operational improvements. Read More.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.